We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

12 hedge funds and large institutions have $6.27M invested in VistaGen Therapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

1.65% less ownership

Funds ownership: 21.25% → 19.6% (-1.6%)

8% less funds holding

Funds holding: 13 → 12 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

51% less capital inflows, than outflows

Capital inflows: $369K | Capital outflows: $755K

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.A. Davidson & Co
D.A. Davidson & Co
Montana
+$221K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$146K
3
UBS Group
UBS Group
Switzerland
+$1.05K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$671K
2
Goldman Sachs
Goldman Sachs
New York
-$51K
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$33.2K

VTGN Hedge Fund Activity: Q4 2016 in Review

12 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2016, worth a combined $6.27M — down 16% from $7.45M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of VTGN and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was D.A. Davidson & Co, adding an estimated $221K. The largest seller was Sabby Management, cutting an estimated $671K.

  • 12 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2016, down from 13 in Q3 2016.
  • Funds reported $6.27M of VistaGen Therapeutics stock for Q4 2016, down 16% quarter-over-quarter.
  • 1 fund opened new VistaGen Therapeutics positions in Q4 2016 and 2 closed out, a net change of -1 holder.
  • The largest VistaGen Therapeutics buyer in Q4 2016 was D.A. Davidson & Co, an estimated $221K added.
  • The largest VistaGen Therapeutics seller in Q4 2016 was Sabby Management, an estimated $671K sold.

Based on aggregated 13F filings for Q4 2016.